WCG Clinical

NOVEMBER 17, 2023

Although the NIH Guidelines were originally written with non-clinical laboratory research in mind, they also apply to human gene transfer (HGT) research, wherein rsNA or rsNA-containing products are administered to research participants. Since then, however, certain genetic engineering technologies (e.g.,

Genome 52

Genome Genomics Gene Editing Genetic Engineering 52

The Pharma Data

JANUARY 19, 2021

A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell , could have implications for gene editing therapies as well. A CRISPR-Cas9 system has two components: the Cas9 guide RNA that directs the system to edit a particular gene, and the CRISPR “scissors” that make the cut.

Bacteria 52

Bacteria Gene Editing Research RNA 52

Bioengineer

JULY 19, 2021

These findings suggest that for therapies to be effective, they must be targeted at both gene products. KRAS encodes two gene products, KRAS4A and KRAS4B, whose levels can vary across organs and embryonic stages. ” KRAS genes in embryonic development. Credit: CNIO.

Research 52

Research Gene Genetic Engineering Genetics 52

Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.

Vaccine 52

Vaccine Vaccination DNA Protein 52

The Pharma Data

JANUARY 27, 2021

“As a clinician, healthcare administrator, biotech entrepreneur and venture capital investor, Steve’s leadership and breadth of experience in the clinical development of cell and gene therapies will be invaluable to PlateletBio as we progress our cell therapy platform into the clinic later this year,” said Sam Rasty, Ph.D.,

Genetic Engineering 40

Genetic Engineering Gene Therapy Gene Engineer 40

pharmaphorum

NOVEMBER 2, 2021

Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed. This lack of complexity also promotes simpler production workflows, offering the advantage of reduced costs and high yields.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 About Juyou Bio – Technology Co. Juyou Bio-Technology Co.,

Licensing 40

Licensing Licensing Dermatology Production 40

Pharmaceutical Technology

JUNE 4, 2023

Innovation S-curve for the pharmaceutical industry Transcription factors for AAV is a key innovation area in pharmaceutical Adeno-associated virus (AAV) vectors are widely used for gene therapy. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins.

Gene 262

Gene Gene Therapy Genetics DNA 262

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. The IBC’s Role in Developing Hazard Communications In its review, the IBC derives these safe product handling answers using a risk assessment.

Genetic Engineering 52

Genetic Engineering Clinical Trials Clinical Trials Engineer 52

Roots Analysis

SEPTEMBER 9, 2024

The rising demand for protein therapeutics, such as monoclonal antibodies and vaccines , is driving advancements in protein expression technology to ensure efficient and scalable production. In the healthcare industry, protein expression technology is primarily used for the production of therapeutic biologics and high-value small molecules.

Protein 40

Protein Gene Production DNA 40

Pharmaceutical Technology

AUGUST 17, 2022

The alliance will merge the cell and media products and process development services of RoosterBio with the worldwide cell and gene therapy manufacturing expertise of AGC. . To create strong and scalable processes for hMSC and exosome therapies, RoosterBio will leverage its broad-ranging cell and media product portfolio.

Manufacturing 130

Manufacturing Gene Therapy Genetic Engineering Gene 130

Roots Analysis

AUGUST 31, 2023

Overview of Gene Switch The notion that genes might be turned on and off was discovered several decades ago when studies revealed that E. Gene switches are sites on genes where regulatory molecules can bind to trigger transcription process, leading to expression of a particular gene.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

Advarra

AUGUST 10, 2023

Rapid growth in gene therapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) prepares to launch Operation Warp Speed for Rare Diseases. From a technical standpoint, such diseases should be easier to treat with current gene therapy technology.

Gene Therapy 52

Gene Therapy Development Gene Drugs 52

Advarra

JANUARY 11, 2024

Personalized medicine using genetic resequencing techniques, such as cell and gene therapies, enables researchers to create more customized therapies for combatting cancer. Only after these trials are successful can sponsors seek market approval for mRNA-based products.

Vaccine 52

Vaccine Vaccination Protein Antibody 52

Advarra

JUNE 13, 2023

Research in gene therapies and genetically engineered drugs and vaccines are growing exponentially, and will only continue to become more popular. The accelerating gene therapy market is expected to grow globally by 16.6% between 2020-2027.

Gene Therapy 52

Gene Therapy Gene Research Genetic Engineering 52

Roots Analysis

OCTOBER 22, 2023

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. ASOs are short single-stranded nucleotides that bind to specific messenger RNAs and prevent the production of a particular protein. RNA therapeutics offer several advantages over small molecules.

RNA 40

RNA Protein Genetics Gene Expression 40

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

Advarra

OCTOBER 10, 2024

These resistance genes are commonly found on small circles of DNA called plasmids. They often carry genes to help the bacteria succeed by giving it a selective advantage, such as bacterial toxins or antibiotic resistance genes. The progeny viruses are released into the environment to await another host to infect.

Bacteria 52

Bacteria Genetics Genetic Engineering Gene 52

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. WCG has many ways to support cell and gene therapy clinical trials for lupus.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

XTalks

NOVEMBER 29, 2024

129 Through this acquisition, Roche secures proprietary technologies such as Poseida’s Cas-CLOVER gene editing platform and in-house good manufacturing practice (GMP) manufacturing capabilities. These resources allow for scalable cell therapy production, ensuring affordability and broader access.

Gene Therapy 100

Gene Therapy Gene Gene Editing Genetic Engineering 100